In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deanna Kamienski

Senior Deals Analyst, Strategic Transactions

Deanna has been with Strategic Transactions since 2000. In her role she researches, analyzes, and writes summaries of alliances, M&A, and fundraising activities among global biopharma and medtech companies. Deanna oversees the two Dealmaking columns and authors a Quarterly Statistics article, in addition to contributing content to In Vivo. Prior to joining Strategic Transactions, Deanna worked at Yale University, first in the Office of Medical Development as a gift support services coordinator assisting in fundraising activities and producing fund reports and donor gift acknowledgements. Later she worked at Yale's Department of Epidemiology and Public Health as a research assistant performing various tasks including editing the School of Public Health's website, identifying new funding prospects, providing grant support for the Dean, and preparing development materials and reports. Deanna holds a Bachelor of Science degree from the University of Vermont. In her spare time she enjoys boating and fishing with her family and friends.
Advertisement
Set Alert for Articles By Deanna Kamienski

Latest From Deanna Kamienski

Pacts In Medtech, March/April 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech highlights notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we look at industry pacts that were sealed in March and April 2018.

Pacts in Medtech Deals

Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate

Biopharma start-ups finally had an increase in financing activity, following three sequential quarters with a decrease. A review of biopharma start-up dealmaking and financing activity from January through March 2018, based on data from Strategic Transactions.

Deals Financing

Deals Shaping The Medical Industry, May 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2018.

Deals Market Intelligence

Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m

April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.

Financing StartUps and SMEs

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing

Deals Shaping The Medical Industry April 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2018. 

Deals BioPharmaceutical
See All
Advertisement
UsernamePublicRestriction

Register